Provided by Tiger Trade Technology Pte. Ltd.

Agios Pharmaceuticals

31.77
-0.1500-0.47%
Volume:145.56K
Turnover:4.63M
Market Cap:1.89B
PE:-4.53
High:32.12
Open:31.85
Low:31.53
Close:31.92
52wk High:46.00
52wk Low:22.24
Shares:59.47M
Float Shares:50.09M
Volume Ratio:0.42
T/O Rate:0.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.0075
EPS(LYR):-7.1203
ROE:-34.34%
ROA:-22.24%
PB:1.84
PE(LYR):-4.46

Loading ...

Analysts Offer Insights on Healthcare Companies: Oncology Institute (TOI) and Agios Pharma (AGIO)

TIPRANKS
·
Jul 07

H.C. Wainwright sees FDA Priority Review as positive signal for Agios’ mitapivat

TIPRANKS
·
Jul 07

Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says

MT Newswires Live
·
Jul 07

Agios Pharmaceuticals Shares Rise 12.4% After US FDA Grants Priority Review to Sickle Cell Disease Drug

THOMSON REUTERS
·
Jul 07

Agios Pharmaceuticals rises 12.9%

TIPRANKS
·
Jul 07

DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday

Benzinga_recent_news
·
Jul 07

Agios Pharmaceuticals price target raised to $41 from $36 at Truist

TIPRANKS
·
Jul 07

U.S. Stocks on the Move-tesla, Nvidia, Rivian

Reuters
·
Jul 07

RBC Capital Adjusts Agios Pharmaceuticals PT to $32 From $28, Maintains Sector Perform Rating

MT Newswires Live
·
Jul 07

Agios Pharmaceuticals granted priority review for mitapivat sNDA

TIPRANKS
·
Jul 07

Agios Pharmaceuticals is Maintained at Buy by B of a Securities

Dow Jones
·
Jul 07

Agios Says FDA Grants Priority Review for Mitapivat Sickle Cell Disease Filing

Reuters
·
Jul 07

Agios Pharmaceuticals - Pdufa Goal Date for Mitapivat Snda is November 1, 2026

THOMSON REUTERS
·
Jul 07

U.S. FDA Grants Priority Review to Agios’ Snda for Mitapivat in Sickle Cell Disease

THOMSON REUTERS
·
Jul 07

Agios Pharmaceuticals Inc : Bofa Global Research Raises Price Objective to $46 from $40

THOMSON REUTERS
·
Jul 07

Agios Pharmaceuticals (AGIO) Could Be 8% Below Fair Value On Growth Index Shift

Simply Wall St.
·
Jul 05

Agios Schedules Q2 2026 Results Conference Call and Webcast

Reuters
·
Jun 29

Agios Pharmaceuticals (AGIO) Is Up 10.3% After New Mitapivat Phase 3 Data and Share Filing – Has The Bull Case Changed?

Simply Wall St.
·
Jun 23

Agios Pharmaceuticals shareholders approve 2 million-share increase to 2023 stock incentive plan

Reuters
·
Jun 19

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 16